QAW039

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

AsthmaAtopic DermatitisAllergic RhinitisAtopic Asthma

1050 competitors in Asthma

#DrugCompanyPhaseTrials

1

QAW039

Novartis

Phase 3

92

Singulair

AstraZeneca

Preclinical

173

Atrovent

Boehringer Ingelheim

Preclinical

54

Symbicort

AstraZeneca

Preclinical

65

Decadron

QQuince Therapeutics S.p.A.

Preclinical

16

Tylenol

KKenvue Brands

Preclinical

17

DUPIXENT

Regeneron

Preclinical

18

Blood Withdrawn

Emergent BioSolutions

Preclinical

19

Fasenra

AstraZeneca

Preclinical

110

Biological Drug

UUniversitaire Ziekenhuizen KU Leuven

Preclinical

1Show 9 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Asthma9 trials

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

Completed·Novartis·Phase 3·NCT03226392·704 enrolled

Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.

Withdrawn·Novartis·Phase 2·NCT03989635

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

Completed·Novartis·Phase 3·NCT02563067·877 enrolled

Show 6 more trials

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

Completed·Novartis·Phase 3·NCT03215758·675 enrolled

Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent Asthma

Completed·Novartis·Phase 2·NCT01545726·61 enrolled

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

Completed·Novartis·Phase 3·NCT02555683·894 enrolled

Dose Finding Study for QAW039 in Asthma

Completed·Novartis·Phase 2·NCT01437735·1,043 enrolled

Systemic Corticosteroids Avoidance Study in Severe Asthma Patients

Terminated·Novartis·Phase 3·NCT03629249·604 enrolled

Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment

Terminated·Novartis·Phase 3·NCT03052517·2,538 enrolled

Eosinophilia1 trial

A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia

Terminated·Novartis·Phase 2·NCT03810183·9 enrolled

Renal Impairment1 trial

Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects

Completed·Novartis·Phase 1·NCT03087942·45 enrolled

Efficacy1 trial

Efficacy, Safety, and Pharmacokinetics of QAW039

Completed·Novartis·Phase 2·NCT01253603·170 enrolled

Atopic Asthma1 trial

A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients

Completed·Novartis·Phase 2·NCT01836471·345 enrolled

2 more indications

Atopic Dermatitis1 trial

Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.

Completed·Novartis·Phase 2·NCT01785602·103 enrolled

Allergic Rhinitis1 trial

A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber

Completed·Novartis·Phase 2·NCT01804400·188 enrolled

Details

Drug Info

Related News